用于乙型肝炎病毒相关急性慢性肝衰竭的人类间充质干细胞

StephenW

Eur J Gastroenterol Hepatol. 2018 May 3. doi: 10.1097/MEG.0000000000001156. [Epub ahead of print]
Human mesenchymal stem cells for hepatitis B virus-related acute-on-chronic liver failure: a systematic review with meta-analysis.
Chen B1, Wang YH, Qian JQ, Wu DB, Chen EQ, Tang H.
Author information

1
    Center of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, People's Republic of China.

Abstract
BACKGROUND AND AIM:

Acute-on-chronic liver failure (ACLF) is a condition with high mortality. New strategies are urgently required. The present review aims to provide a comprehensive understanding of the efficacy and safety of mesenchymal stem cells (MSC) treatment in patients with ACLF associated with hepatitis B virus infection.
MATERIALS AND METHODS:

The MEDLINE, Embase, and Cochrane Library databases were searched for the relevant publications. If appropriate, a meta-analysis was carried out for the following outcomes: survival rate, model for end-stage liver disease score, and liver function.
RESULTS:

Three studies were eligible for the present systematic review. A total of 198 hepatitis B virus-ACLF patients were enrolled for this review. Ninety-one patients were treated with MSC and 107 patients were treated with standard medical therapy (SMT) as controls. Pooled results showed that MSC treatment could significantly reduce the mortality rate at week 12 [risk ratio: 0.50; 95% confidence interval (CI): 0.33, 0.76; P=0.00009] and the mortality rate at the final follow-up (risk ratio: 0.54; 95%CI: 0.37, 0.78; P=0.001) compared with the SMT group. Furthermore, pooled estimates showed that MSC treatment could significantly reduce the total bilirubin level at week 4 (mean difference: 58.89; 95%CI: 14.47, 103.32; P=0.009) compared with the SMT group. No severe complication associated with MSC treatment was observed.
CONCLUSION:

Our pooled results suggested that MSC treatment could significantly reduce the mortality rate, without increasing the incidence of severe complications.

PMID:
    29727380
DOI:
    10.1097/MEG.0000000000001156

StephenW

Eur J Gastroenterol Hepatol。 2018年5月3日：doi：10.1097 / MEG.0000000000001156。 [电子版提前打印]
用于乙型肝炎病毒相关急性慢性肝衰竭的人类间充质干细胞：一项系统综述与荟萃分析。
陈B1，王烨华，钱瑾琦，吴斌，陈娥卿，唐H.
作者信息

1
    四川大学华西医院传染病中心，成都，中华人民共和国。

抽象
背景和目的：

急慢性肝衰竭（ACLF）是一种死亡率高的疾病。迫切需要新的战略。本综述旨在全面了解骨髓间充质干细胞（MSC）治疗与乙型肝炎病毒感染相关的ACLF患者的疗效和安全性。
材料和方法：

MEDLINE，Embase和Cochrane图书馆数据库被搜索相关出版物。如果合适的话，对以下结果进行荟萃分析：存活率，终末期肝病评分模型和肝功能。
结果：

三项研究有资格进行目前的系统评价。本研究共纳入198名乙型肝炎病毒ACLF患者。 91名患者接受MSC治疗，107名患者接受标准药物治疗（SMT）作为对照。汇总的结果显示，MSC治疗可以显着降低第12周的死亡率[风险比率：0.50; 95％置信区间（CI）：0.33,0.76;与SMT组相比，最终随访时的死亡率（风险比：0.54; 95％CI：0.37,0.78; P = 0.001）。此外，汇总的估计表明，与SMT组相比，MSC治疗可以显着降低第4周的总胆红素水平（平均差异：58.89; 95％CI：14.47,103.32; P = 0.009）。未观察到与MSC治疗相关的严重并发症。
结论：

我们的汇总结果表明，MSC治疗可以显着降低死亡率，而不会增加严重并发症的发生率。

结论：
    29727380
DOI：
    10.1097 / MEG.0000000000001156